{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:15:28Z","timestamp":1773260128699,"version":"3.50.1"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20210101339JC"],"award-info":[{"award-number":["20210101339JC"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>It has been nearly 35 months since the COVID-19 outbreak. The pathogen SARS-CoV-2 has evolved into several variants. Among them, Omicron is the fifth variant of concern which have rapidly spread globally during the past 8 months. Omicron variant shows different characteristics from previous variants, which is highly infectious, highly transmissible, minimally pathogenic, vaccine and antibody tolerant; however, it is less likely to cause severe illness, resulting in fewer deaths. Omicron has evolved into five main lineages, including BA.1, BA.2, BA.3, BA.4, and BA.5. Before BA.5, Omicron BA.2 sublineage was the dominant strain all over the world for several months. The experience of prevention and treatment against BA.2 is worth studying and learning for overcoming other Omicron subvariants. Although the Omicron subvariant BA.2 is significantly less severe than that caused by ancestral strains, it is still far more dangerous than influenza, and its long-term sequelae are unknown. Effective treatments are currently limited; therefore, effective defense may be the key to controlling the epidemic today, rather than just \u201cliving with\u201d the virus.<\/jats:p>","DOI":"10.3389\/fpubh.2022.1039123","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:34:42Z","timestamp":1669278882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?"],"prefix":"10.3389","volume":"10","author":[{"given":"Ren","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/jocs.15147","article-title":"ECMO therapy in COVID-19: an experience from Zurich","volume":"36","author":"Sromicki","year":"2021","journal-title":"J Card Surg."},{"key":"B2","article-title":"Emerging dominant SARS-CoV-2 variants","author":"Chen","year":"2022","journal-title":"arXiv [Preprint]"},{"key":"B3","doi-asserted-by":"publisher","first-page":"104585","DOI":"10.1016\/j.jcv.2020.104585","article-title":"SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies","volume":"131","author":"Karamitros","year":"2020","journal-title":"J Clin Virol"},{"key":"B4","author":"Cascella","year":"2022","journal-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls"},{"key":"B5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/jobm.202000537","article-title":"SARS-CoV-2, the pandemic coronavirus: molecular and structural insights","volume":"61","author":"Kadam","year":"2021","journal-title":"J Basic Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/v13112188","article-title":"Interspecies jumping of bat coronaviruses","volume":"13","author":"Wong","year":"2021","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.cub.2020.03.022","article-title":"Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak","volume":"30","author":"Zhang","year":"2020","journal-title":"Curr Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","article-title":"Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins","volume":"583","author":"Lam","year":"2020","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1007236","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathog."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microbes Infect."},{"key":"B13","author":"Aleem","year":"","journal-title":"Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e202200059","DOI":"10.1002\/cbic.202200059","article-title":"Challenges of the Omicron (B","volume":"1","author":"Mohapatra","year":"2022","journal-title":"Chembiochem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.043","article-title":"tracking Changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 Virus","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/mco2.110","article-title":"SARS-CoV-2 Omicron variant: characteristics and prevention","volume":"2","author":"He","year":"2020","journal-title":"MedComm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15585\/mmwr.mm7003e2","article-title":"Emergence of SARS-CoV-2 B","volume":"70","author":"Galloway","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B","volume":"593","author":"Volz","year":"2021","journal-title":"117 in England Nature."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B","volume":"593","author":"Davies","year":"2021","journal-title":"117 Nature."},{"key":"B23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.25.427948","article-title":"mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants","author":"Wu","year":"2021","journal-title":"bioRxiv [Preprint]."},{"key":"B25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.15585\/mmwr.mm7008e2","article-title":"Detection of B","volume":"70","author":"Mwenda","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.26.21252554","article-title":"Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil","author":"Faria","year":"2021","journal-title":"medRxiv [Preprint]."},{"key":"B27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased resistance of SARS-CoV-2 variant P","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature."},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0262-4079(22)00030-6","article-title":"Understanding omicron","volume":"253","author":"Page","year":"2022","journal-title":"New Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","article-title":"Heavily mutated Omicron variant puts scientists on alert","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.26355\/eurrev_202112_27653","article-title":"Omicron (B","volume":"25","author":"Kannan","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1375091\/v1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron\/BA","author":"Kawaoka","year":"2022","journal-title":"Res Sq"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2200181","DOI":"10.2807\/1560-7917.ES.2022.27.10.2200181","article-title":"Molecular epidemiology of the SARS-CoV-2 variant Omicron BA","volume":"27","author":"Fonager","year":"2022","journal-title":"Euro Surveill"},{"key":"B34","doi-asserted-by":"publisher","first-page":"106261","DOI":"10.1016\/j.ijsu.2022.106261","article-title":"The Omicron subvariant BA","volume":"99","author":"Rahimi","year":"2022","journal-title":"Int J Surg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.26355\/eurrev_202112_27652","article-title":"Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ajpath.2022.01.007","article-title":"Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome Coronavirus 2 in Houston, Texas","volume":"192","author":"Christensen","year":"2022","journal-title":"Am J Pathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/s2666-5247(22)00060-x","article-title":"Serum neutralization of the SARS-CoV-2 omicron sublineage BA","volume":"22","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"B38","doi-asserted-by":"publisher","first-page":"o358","DOI":"10.1136\/bmj.o358","article-title":"Covid-19: What do we know about omicron sublineages?","volume":"376","author":"Mahase","year":"2022","journal-title":"BMJ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"106581","DOI":"10.1016\/j.ijsu.2022.106581","article-title":"Priyanka, Choudhary OP. Emergence of Omicron sub-variant BA2: Is it a matter of concern amid the COVID-19 pandemic?","volume":"99","author":"Dhawan","year":"2022","journal-title":"Int J Surg."},{"key":"B40","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.xcrm.2022.100679","article-title":"Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA","volume":"608","author":"Cao","year":"2022","journal-title":"Nature."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac203","article-title":"Rapid spread of SARS-CoV-2 Omicron subvariant BA","author":"Cheng","year":"2022","journal-title":"Clin Infect Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMc2201933","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA","volume":"386","author":"Takashita","year":"2022","journal-title":"2 N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature."},{"key":"B45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/s0140-6736(22)00327-0","article-title":"Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study","volume":"399","author":"Menni","year":"2022","journal-title":"Lancet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jmv.27760","article-title":"The severity of the first 207 infections with the SARS-CoV-2 Omicron BA","volume":"24","author":"Gautret","year":"2022","journal-title":"J Med Virol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.xcrm.2022.100529","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","volume":"3","author":"Edara","year":"2022","journal-title":"Cell Rep Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B","volume":"28","author":"Lewnard","year":"2022","journal-title":"Nat Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jtm\/taac068","article-title":"Effects of BA","volume":"29","author":"Qassim","year":"2022","journal-title":"J Travel Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1473-3099(22)00309-7","article-title":"COVID-19 vaccine effectiveness against the omicron (BA","volume":"22","author":"Kirsebom","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"931","DOI":"10.15585\/mmwr.mm7129e1","article-title":"Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s2213-2600(20)30527-0","article-title":"Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study","volume":"9","author":"Piroth","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1631\/jzus.B2000479","article-title":"Comparison of COVID-19 and influenza characteristics","volume":"22","author":"Bai","year":"2021","journal-title":"J Zhejiang Univ Sci B."},{"key":"B57","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3906\/sag-2004-146","article-title":"COVID-19: Prevention and control measures in community","volume":"50","author":"G\u00fcner","year":"2020","journal-title":"Turk J Med Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1002\/jmv.27749","article-title":"\u201cIs Omicron mild\u201d? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies","volume":"94","author":"Rajpal","year":"2022","journal-title":"J Med Virol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5582\/bst.2021.01269","article-title":"Infectious disease activity during the COVID-19 epidemic in Japan: Lessons learned from prevention and control measures","volume":"15","author":"Sawakami","year":"2021","journal-title":"Biosci Trends."},{"key":"B60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.35772\/ghm.2021.01066","article-title":"Behavioral changes adopted to constrain COVID-19 in Japan: What are the implications for seasonal influenza prevention and control?","volume":"3","author":"Sawakami","year":"2021","journal-title":"Glob Health Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-020-00475-6","article-title":"Airborne transmission of COVID-19 and the role of face mask to prevent it: a systematic review and meta-analysis","volume":"26","author":"Tabatabaeizadeh","year":"2021","journal-title":"Eur J Med Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fmb-2020-0292","article-title":"COVID-19: mask efficacy is dependent on both fabric and fit","volume":"16","author":"Darby","year":"2021","journal-title":"Future Microbiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e2115985","DOI":"10.1001\/jamanetworkopen.2021.15985","article-title":"Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization","volume":"4","author":"Chodick","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/v13020202","article-title":"COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention","volume":"13","author":"Sharma","year":"2021","journal-title":"Viruses."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e12481","DOI":"10.15252\/emmm.202012481","article-title":"Why does Japan have so few cases of COVID-19?","volume":"12","author":"Iwasaki","year":"2020","journal-title":"EMBO Mol Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"Cd013574","DOI":"10.1002\/14651858.CD013574.pub2","article-title":"Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review","volume":"9","author":"Nussbaumer-Streit","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/s0140-6736(20)30460-8","article-title":"The psychological impact of quarantine and how to reduce it: rapid review of the evidence","volume":"395","author":"Brooks","year":"2020","journal-title":"Lancet."},{"key":"B68","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/s1473-3099(20)30428-x","article-title":"COVID-19: when should quarantine be enforced?","volume":"20","author":"Bauch","year":"2020","journal-title":"Lancet Infect Dis."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1039123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:34:47Z","timestamp":1669278887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1039123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":68,"alternative-id":["10.3389\/fpubh.2022.1039123"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.1039123","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"1039123"}}